findmyKOL

Charles Loprinzi, MD

Enriched profile

Regis Professor of Breast Cancer Research (Emeritus Chair, Division of Medical Oncology; Emeritus Vice-Chair, Department of Oncology) -- recently retired per 2026 award coverage · Mayo Clinic

ORCIDNPI
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyMedical OncologyFocusCancer Treatment and Pharmacology+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding1994–2024

Charles Loprinzi is Regis Professor of Breast Cancer Research (Emeritus Chair, Division of Medical Oncology; Emeritus Vice-Chair, Department of Oncology) -- recently retired per 2026 award coverage at Mayo Clinic. OpenAlex indexes 843 publications with 49,105 citations (h-index 108); ClinicalTrials.gov lists 37 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Charles L. Loprinzi, MD, is Regis Professor of Breast Cancer Research (Emeritus Chair, Division of Medical Oncology at Mayo Clinic, Rochester, Minnesota. The public record shows 843 publications with 49,105 citations (h-index 108), centered on Cancer Treatment and Pharmacology, Estrogen and related hormone effects, Menopause: Health Impacts and Treatments. It also documents an investigator role on 37 registered clinical trials, industry payments reported by 8 companies, 4 NIH-funded awards (1994–2024).

  • Most recent indexed publication: 2026 · Journal of clinical oncology
  • Top research focus: Cancer Treatment and Pharmacology
  • 37 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 8 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer13 trialsPain12 trialsHot Flashes8 trialsColorectal Cancer2 trialsRectal Neoplasms2 trialsProstate Cancer2 trialsOsteoporosis2 trialsLeukemia (AML/ALL/CML/CLL)2 trialsLymphoma2 trialsMultiple Myeloma2 trialsFatigue1 trialSleep Wake Disorders1 trialMelanoma1 trialArthralgia1 trialAcute Pain1 trialOvarian / Gynecologic Cancer1 trialFallopian Tube Neoplasms1 trialBreast Carcinoma In Situ1 trialCarcinoma in Situ1 trialHypesthesia1 trial

Research focus

OpenAlex concept fingerprint
Cancer Treatment and PharmacologyEstrogen and related hormone effectsMenopause: Health Impacts and TreatmentsChemotherapy-related skin toxicityColorectal Cancer Treatments and Studies

Drugs & molecules

across trials, industry payments and publications
Envarsusgeneric · TacrolimusClinical trialsIndustry payments3PublicationsEnhertugeneric · TrastuzumabClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Alliance for Clinical Trials in OncologyClinical trials18Industry paymentsMayo ClinicClinical trials15Industry paymentsAcademic and Community Cancer Research UnitedClinical trials4Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
843publications

Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.

49,105citations

Total citations across indexed works.

108h-index

Hirsch index (OpenAlex). i10-index 429.

Clinical & industry

trials, payments and federal funding
37clinical trials

Investigator role on registered studies.

View trials
8companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
4NIH grants · 1994–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 37 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2019)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor100%
    Anastrozole100%
    Part D<11 patients

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

4 NIH research awards on record, funded 19942024 per NIH RePORTER. The latest:

58 more award records behind the reveal.Reveal →

Congress activity

Updated 27 Aug 2026

131 congress contributions (1999–2025) across AACR, ASCO, ASH, ASTRO, SABCS per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Jeff A. Sloan175Debra L. Barton119Paul J. Novotny106

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/charles-loprinzi-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/charles-loprinzi-67924120

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Charles-Loprinzi

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Other

    mayoclinic.elsevierpure.com/en/persons/charles-lawrence-loprinzi

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.elsevierpure.com
  • Other

    oncologytube.com/charles-loprinzi-md-mayoclinic-miamibreast22-breast22-cipn-chemotherapy-induced-neuropathy

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com
  • Apple Podcasts

    podcasts.apple.com/us/podcast/managing-cancer-cachexia-with-charles-loprinzi-md/id1334855695

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com
12 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
21 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
35 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
4 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
21 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.